In recent years, B7-H3 has been extensively studied as a negative modulator in tumor immunity.[30] B7-H3 protein is expressed in many tumor tissues, such as lung cancer, gastric cancer, kidney cancer, prostate cancer, and neuroblastoma.[31,32] Studies on B7-H3 expression in gastric cancer have indicated that ectopic expression of B7-H3 is closely related to tumor progression and poor prognosis.[33,34] B7-H3 overexpression has been linked to poor prognosis in human patients and to the invasive and metastatic potential of tumors in vitro models. Here, CD276 is linked to Familial prostate cancer.